Advertisement
Monday, November 16, 2026NewslettersAdvertiseWatch FL1
GET LOCALGo ad-freeHigh school sportsLocal eventsObituaries
News

FDA gives approval to first-ever gene therapy for Duchenne Muscular Dystrophy

FDA gives approval to first-ever gene therapy for Duchenne Muscular Dystrophy

The U.S. Food and Drug Administration has granted accelerated approval for the first-ever gene therapy, Elevidys, targeting Duchenne Muscular Dystrophy.


This groundbreaking development has been facilitated by research conducted in Rochester, and the therapy underwent phase three of its clinical trial at the University of Rochester Medical Center (URMC).

The approval will benefit pediatric patients aged four and five diagnosed with DMD, a debilitating condition that primarily affects boys, often leading to loss of mobility by their teenage years.


This gene therapy aims to replace the faulty gene responsible for the disease, marking a significant advancement from traditional symptomatic treatments.

Notably, participating families have reported significant improvements post-infusion.

Clinical trials continue as the makers of Elevidys work toward securing full approval for the therapy for children up to seven years old.

Categories: NewsHealth

Want to go ad-free?

Become an FL1 member and say goodbye to ads! Plus, you’ll be supporting a company rooted in the Finger Lakes for nearly 30 years.

$4.99 / month

Get ad-free access

Renews monthly. Cancel anytime through your account. Already contributing via Google? Sign in with your Google account and unlock ad-free access. Embedded YouTube videos and other third-party media players may still contain ads.

Start your day with FingerLakes1

Get the stories that matter from across the Finger Lakes, delivered to your inbox.

Your email will be added to our newsletter mailing list, hosted on Substack. Privacy policy